Characterization of the Gut Microbiota of Individuals at Different T2D Stages Reveals a Complex Relationship with the Host.

In this work, we studied 217 Mexican subjects divided into six groups with different stages of glucose intolerance: 76 Controls (CO), 54 prediabetes (PRE), 14 T2D no medication (T2D-No-M), 14 T2D with Metformin (T2D-M), 22 T2D with polypharmacy (T2D-P), and 37 T2D with polypharmacy and insulin (T2D-P+I). We aimed to determine differences in the gut microbiota diversity for each condition. At the phylum level, we found that Firmicutes and Bacteroidetes outline major changes in the gut microbiota. The gut bacterial richness and diversity of individuals in the T2D-No-M group were lesser than other groups. Interestingly, we found a significant difference in the beta diversity of the gut microbiota among all groups. Higher abundance was found for Comamonadaceae in PRE, and Sutterella spp. in T2D-No-M. In addition, we found associations of specific microbial taxa with clinical parameters. Finally, we report predicted metabolic pathways of gut microbiota linked to T2D-M and PRE conditions. Collectively, these results indicate that each group has specific predicted metabolic characteristics and gut bacteria populations for each phenotype. The results of this study could be used to define strategies to modulate gut microbiota through noninvasive treatments, such as dietary intervention, probiotics or prebiotics, and to improve glucose tolerance of individuals with prediabetes or T2D.

Evaluación de la Escala EFD-66 como herramienta para predecir la adherencia al tratamiento en pacientes con enfermedades crónicas no transmisibles

Objetivo. Los objetivos del presente estudio son validar la construcción de la escala de fases de duelo (EFD-66) como instrumento para medir las etapas de duelo (ED) y evaluar su utilidad para discriminar entre pacientes con enfermedad crónica no transmisible (ECNT) que cumplen con adherencia al tratamiento farmacológico (ATF) en la consulta médica ambulatoria. Métodos. Se realizó un estudio transversal para determinar la asociación entre las ED y la ATF, en los meses de abril a octubre de 2015. La recogida de datos se realizó mediante un diseño prolectivo. Se aplicaron tres instrumentos: una cédula sociodemográfica, la escala EFD-66 y el cuestionario de Morisky-Green. Se reclutaron pacientes con antecedente de ECNT procedentes de la Clínica de Medicina Familiar “Gustavo A. Madero”, en la Ciudad de México. Los datos se analizaron con las pruebas estadísticas apropiadas. Resultados. Se incluyó un total de 165 pacientes. Se observó que altos puntajes en las subescalas de negación (razón de momios [RM]: 1,124; intervalo de confianza de 95% [IC95%]: 1,066-1,186; P < 0,001), de ira (RM: 1,157; IC95%: 1,080-1,240; P < 0,001) y de depresión (RM: 1,071; IC95%: 1,029-1,116; P = 0,001) se asocian con falta de ATF; sin embargo, un puntaje elevado en la subescala de aceptación (RM: 0,913; IC95%: 0,880-0,948; P < 0,001) se asocia con ATF. La mayor sensibilidad entre las subescalas se observó en las etapas de negación e ira (área bajo la curva [ABC]: 0,597 en ambas). Conclusiones. La EFD-66 es un instrumento que presenta una buena validez de construcción como instrumento para medir las ED y permite detectar pacientes con ECNT que cumplen con ATF, por lo que recomendamos su aplicación en la consulta médica ambulatoria. Además, nuestros hallazgos indican que el duelo es un factor de riesgo que incrementa la falta de ATF.

Objective. The objectives of this study are to validate the construct of the stages of grief scale (FD-66) as an instrument for measuring the stages of grief and to evaluate its usefulness in discriminating among patients with chronic non-communicable diseases in terms of adherence to the pharmacological treatment prescribed. Methods. A cross-sectional study was conducted from April to October 2015 to determine the association between the stages of grief and treatment adherence. Data were collected using a prolective design. Three instruments were applied: a sociodemographic document, the FD-66 scale, and the Morisky-Green questionnaire. Patients with a history of CNCDs were recruited from the Gustavo A. Madero Family Medicine Clinic in Mexico City. The data were analyzed using the appropriate statistical tests. Results. A total of 165 patients were included. It was observed that high scores on the subscales of denial (odds ratio [OR]: 1.124; confidence interval of 95% [CI95%]: 1.066-1.186; P < 0,001); anger (OR: 1.157; CI95%: 1.080-1.240; P < 0.001), and depression (OR: 1.071; CI95%: 1.029-1.116; P = 0.001) are associated with poor treatment adherence; however, a high score on the acceptance subscale (OR: 0.913; CI95%: 0.880-0.948; P < 0.001) is associated with good treatment adherence. The greatest sensitivity among the subscales was observed in the denial and anger stages (area under the [ABC] curve: 0.597 in both). Conclusions. The FD-66 is an instrument with good construct validity as a tool for measuring the stages of grief and makes it possible to identify patients with CNCD that will adhere to treatment. We therefore recommend its use in outpatient medical consultations. Furthermore, our findings indicate that grief is a risk factor that increases poor treatment adherence.

Objetivo. Validar a construção da Escala facial de dor (EFD-66) como instrumento para medir as fases da dor e avaliar sua utilidade para discriminar, na consulta médica ambulatorial, os pacientes com doenças crônicas não transmissíveis (DCNT) que aderem ao tratamento medicamentoso. Métodos. Estudo transversal para determinar a associação entre as fases da dor e o tratamento medicamentoso conduzido de abril a outubro de 2015. A coleta de dados foi realizada prospectivamente. Foram aplicados três instrumentos: uma ficha sociodemográfica, a escala EFD-66 e o teste de Morisky-Green. Foram recrutados pacientes com história de DCNT provenientes da Clínica de Medicina da Família “Gustavo A. Madero”, na Cidade do México. Os dados foram analisados com os testes estatísticos apropriados. Resultados. Foi estudada uma amostra de 165 pacientes. Observou-se que uma pontuação alta nas subescalas de negação (odds ratio [OR] 1,124; intervalo de confiança de 95% [IC95%] 1,066–1,186; P < 0,001), raiva (OR 1,157; IC95% 1,080–1,240; P < 0,001) e depressão (OR 1,071; IC95% 1,029–1,116; P = 0,001) está associada à não adesão ao tratamento medicamentoso. No entanto, uma pontuação alta na subescala de aceitação (OR 0,913; IC95% 0,880–0,948; P < 0,001) está associada à adesão ao tratamento medicamentoso. As subescalas com maior sensibilidade foram as fases de negação e raiva (área sob a curva [ASC]: 0,597 em ambas). Conclusões. A escala EFD-66 tem boa validade de construção como instrumento para medir as fases da dor e permite discriminar os pacientes com DCNT que aderem ao tratamento medicamentosos. Assim, recomendamos que esta escala seja aplicada em consultas médicas ambulatoriais. Além disso, nossos achados indicam que a dor é um fator de risco que contribui para a não adesão ao tratamento medicamentoso.

[Evaluation of the FD-66 Scale as a tool for predicting treatment adherence in patients with chronic non-communicable diseasesAvaliação da escala EFD-66 como instrumento para predizer a adesão ao tratamento em pacientes com doenças crônicas não transmissíveis]. / Evaluación de la Escala EFD-66 como herramienta para predecir la adherencia al tratamiento en pacientes con enfermedades crónicas no transmisibles.

OBJECTIVE: The objectives of this study are to validate the construct of the stages of grief scale (FD-66) as an instrument for measuring the stages of grief and to evaluate its usefulness in discriminating among patients with chronic non-communicable diseases in terms of adherence to the pharmacological treatment prescribed. METHODS: A cross-sectional study was conducted from April to October 2015 to determine the association between the stages of grief and treatment adherence. Data were collected using a prolective design. Three instruments were applied: a sociodemographic document, the FD-66 scale, and the Morisky-Green questionnaire. Patients with a history of CNCDs were recruited from the Gustavo A. Madero Family Medicine Clinic in Mexico City. The data were analyzed using the appropriate statistical tests. RESULTS: A total of 165 patients were included. It was observed that high scores on the subscales of denial (odds ratio [OR]: 1.124; confidence interval of 95% [CI95%]: 1.066-1.186; P < 0,001); anger (OR: 1.157; CI95%: 1.080-1.240; P < 0.001), and depression (OR: 1.071; CI95%: 1.029-1.116; P = 0.001) are associated with poor treatment adherence; however, a high score on the acceptance subscale (OR: 0.913; CI95%: 0.880-0.948; P < 0.001) is associated with good treatment adherence. The greatest sensitivity among the subscales was observed in the denial and anger stages (area under the [ABC] curve: 0.597 in both). CONCLUSIONS: The FD-66 is an instrument with good construct validity as a tool for measuring the stages of grief and makes it possible to identify patients with CNCD that will adhere to treatment. We therefore recommend its use in outpatient medical consultations. Furthermore, our findings indicate that grief is a risk factor that increases poor treatment adherence.

OBJETIVO: Validar a construção da Escala facial de dor (EFD-66) como instrumento para medir as fases da dor e avaliar sua utilidade para discriminar, na consulta médica ambulatorial, os pacientes com doenças crônicas não transmissíveis (DCNT) que aderem ao tratamento medicamentoso. MÉTODOS: Estudo transversal para determinar a associação entre as fases da dor e o tratamento medicamentoso conduzido de abril a outubro de 2015. A coleta de dados foi realizada prospectivamente. Foram aplicados três instrumentos: uma ficha sociodemográfica, a escala EFD-66 e o teste de Morisky-Green. Foram recrutados pacientes com história de DCNT provenientes da Clínica de Medicina da Família "Gustavo A. Madero", na Cidade do México. Os dados foram analisados com os testes estatísticos apropriados. RESULTADOS: Foi estudada uma amostra de 165 pacientes. Observou-se que uma pontuação alta nas subescalas de negação (odds ratio [OR] 1,124; intervalo de confiança de 95% [IC95%] 1,066­1,186; P < 0,001), raiva (OR 1,157; IC95% 1,080­1,240; P < 0,001) e depressão (OR 1,071; IC95% 1,029­1,116; P = 0,001) está associada à não adesão ao tratamento medicamentoso. No entanto, uma pontuação alta na subescala de aceitação (OR 0,913; IC95% 0,880­0,948; P < 0,001) está associada à adesão ao tratamento medicamentoso. As subescalas com maior sensibilidade foram as fases de negação e raiva (área sob a curva [ASC]: 0,597 em ambas). CONCLUSÕES: A escala EFD-66 tem boa validade de construção como instrumento para medir as fases da dor e permite discriminar os pacientes com DCNT que aderem ao tratamento medicamentosos. Assim, recomendamos que esta escala seja aplicada em consultas médicas ambulatoriais. Além disso, nossos achados indicam que a dor é um fator de risco que contribui para a não adesão ao tratamento medicamentoso.

Infección por el virus del papiloma humano y su correlación con situaciones ginecológicas u obstétricas de relevancia clínica: estudio transversal / Human papillomavirus infection and its correlates with clinically relevant gynecological and obstetric conditions: A cross-sectional study

Antecedentes y objetivo: Analizar la prevalencia de la infección por el virus del papiloma humano (VPH) y la posible asociación epidemiológica con las situaciones de relevancia clínica en las mujeres. Material y métodos: Se llevó a cabo un estudio transversal en la ciudad de México desde enero de 2012 a diciembre de 2014. Se realizó la detección molecular del VPH sobre muestras cervicales. Los datos se analizaron utilizando las pruebas estadísticas adecuadas. Resultados: Se analizó a un total de 1.604 mujeres (mediana 47, rango intercuartílico 38-54). La prevalencia global de infección para cualquier VPH fue del 9,91% (IC 95% 8,6-11,3). Se calculó la asociación entre la infección por VPH-16 y el número de abortos (NA) (OR=1,427; IC 95% 1,091-1,866) mediante el univariate regression model (UVRM, ‘modelo de regresión univariada’). Además, la menarquia (OR=1,566; IC 95% 1,079-2,272), el NA (OR=1,570; IC 95% 1,106-2,227) y el número de embarazos (NE) (OR=0,461; IC 95% 0,260-0,818) tienen una asociación directa e inversa con la infección con el genotipo 18 del VPH, respectivamente. También, la infección por los genotipos VPH-HR tiene una asociación inversa con el NE (OR=0,791; IC 95% 0,707-0,884), los partos normales (OR=0,867; IC 95% 0,767-0,979) y el NA (OR=0,715; IC 95% 0,534-0,959) (UVRM), y una asociación directa con el número de parejas sexuales (OR=1,082; IC 95% 1,015-1,154). El inicio de la actividad sexual tiene una asociación inversa con la infección por el genotipo 16 (UVRM: OR=0,814; IC 95% 0,715-0,926; multinomial regression model (MNRM, ‘modelo de regresión multinomial’): OR=0,803; IC 95% 0,702-0,918) y VPH-HR (UVRM: OR=0,933; IC 95% 0,889-0,980; y MNRM: OR=0,912; IC 95% 0,867-0,959). Todos los valores de p fueron inferiores a 0,03. Conclusiones: La prevalencia de la infección cervical por VPH es diferente en relación con la edad, y está asociada a diversas situaciones médicas de relevancia clínica en las mujeres (AU)

Background and objective: To analyze the prevalence of human papillomavirus (HPV) infection and the possible epidemiological association with conditions of clinical relevance in women. Material and methods: A cross-sectional study from Mexico City was conducted from January 2012 to December 2014. HPV molecular detection was performed on cervical samples. Data were analyzed with appropriated statistic tests. Results: A total of 1,604 females (median 47, interquartile range 38-54) were analyzed. Global prevalence of infection for any HPV is 9.91% (95% CI 8.6-11.3). An association between infection with 16-HPV and number of abortions (NA) (OR=1.427; 95% CI 1.091-1.866), by univariate regression model (UVRM) was estimated. Moreover, menarche (OR=1.566; 95% CI 1.079-2.272), NA (OR=1.570; 95% CI 1.106-2.227) and number of pregnancies (NP) (OR=0.461; 95% CI 0.260-0.818) have a direct and inverse association with infection by genotype 18 of HPV, respectively. Also, infection with HR-HPV genotypes has an inverse association with NP (OR=0.791; 95% CI 0.707-0.884) by normal labor (OR=0.867; 95% CI 0.767-0.979) and NA (OR=0.715; 95% CI 0.534-0.959) (UVRM), and a direct association with number of sexual partners (OR=1.082; 95% CI 1.015-1.154). Onset of sexual activity has an inverse association with infection by genotype 16- (UVRM: OR=0.814; 95% CI 0.715-0.926; multinomial regression model (MNRM): OR=0.803; 95% CI 0.702-0.918) and HR-HPV (UVRM: OR=0.933; 95% CI 0.889-0.980, and MNRM: OR=0.912; 95% CI 0.867-0.959), allP values were lower than .03. Conclusions: Prevalence of HPV cervical infection is different according to age and it is associated with several medical conditions of clinical relevance in women (AU)

[Human papillomavirus infection and its correlates with clinically relevant gynecological and obstetric conditions: A cross-sectional study]. / Infección por el virus del papiloma humano y su correlación con situaciones ginecológicas u obstétricas de relevancia clínica: estudio transversal.

BACKGROUND AND OBJETIVE: To analyze the prevalence of human papillomavirus (HPV) infection and the possible epidemiological association with conditions of clinical relevance in women. MATERIAL AND METHODS: A cross-sectional study from Mexico City was conducted from January 2012 to December 2014. HPV molecular detection was performed on cervical samples. Data were analyzed with appropriated statistic tests. RESULTS: A total of 1,604 females (median 47, interquartile range 38-54) were analyzed. Global prevalence of infection for any HPV is 9.91% (95% CI 8.6-11.3). An association between infection with 16-HPV and number of abortions (NA) (OR=1.427; 95% CI 1.091-1.866), by univariate regression model (UVRM) was estimated. Moreover, menarche (OR=1.566; 95% CI 1.079-2.272), NA (OR=1.570; 95% CI 1.106-2.227) and number of pregnancies (NP) (OR=0.461; 95% CI 0.260-0.818) have a direct and inverse association with infection by genotype 18 of HPV, respectively. Also, infection with HR-HPV genotypes has an inverse association with NP (OR=0.791; 95% CI 0.707-0.884) by normal labor (OR=0.867; 95% CI 0.767-0.979) and NA (OR=0.715; 95% CI 0.534-0.959) (UVRM), and a direct association with number of sexual partners (OR=1.082; 95% CI 1.015-1.154). Onset of sexual activity has an inverse association with infection by genotype 16- (UVRM: OR=0.814; 95% CI 0.715-0.926; multinomial regression model (MNRM): OR=0.803; 95% CI 0.702-0.918) and HR-HPV (UVRM: OR=0.933; 95% CI 0.889-0.980, and MNRM: OR=0.912; 95% CI 0.867-0.959), all P values were lower than .03. CONCLUSIONS: Prevalence of HPV cervical infection is different according to age and it is associated with several medical conditions of clinical relevance in women.

Criterio diagnóstico para hipoalfalipoproteinemia y punto de corte asociado con protección cardiovascular en una población mestiza mexicana / Diagnostic criteria for hypoalphalipoproteinemia and the threshold associated with cardiovascular protection in a Mexican Mestizo population

Fundamento y objetivos: En las poblaciones mestiza e indígena mexicanas se desconocen los criterios diagnósticos y el riesgo asociado a infarto de miocardio (IM) para el colesterol unido a lipoproteínas de alta densidad (colesterol HDL). El objetivo de este estudio fue establecer, en una población de adultos mexicanos sin factores de riesgo cardiovascular, las concentraciones de colesterol HDL, los criterios diagnósticos para hipoalfalipoproteinemia y prevalencia con base al percentil-10 y al riesgo asociado a IM, y el punto de corte asociado con protección cardiovascular.Sujetos y método: Se determinaron las concentraciones séricas de colesterol HDL promedio en 826 mestizos, 98 indígenas y 155 mestizos con IM de primera vez. Se realizaron los análisis de percentiles y estadísticos correspondientes. Resultados: Las concentraciones promedio de colesterol HDL en mestizos e indígenas fueron: 43,2 y 37,2mg/dl y las inferiores del percentil-10 <30 y <26mg/dl, respectivamente. En mestizos, las concentraciones de colesterol HDL ≤35mg/dl (odds ratio [OR] 1,91, intervalo de confianza del 95% [IC 95%] 1,3-2,8, p=0,001) se asociaron con IM y las >35mg/dl (OR 0,52, IC 95% 0,36-0,76, p=0,001) con una protección cardiovascular del 52%. Las prevalencias de hipoalfalipoproteinemia en mestizos e indígenas fueron para el criterio diagnóstico del percentil-10 del 9 y 11%, y para el asociado a IM del 26 y 54%, respectivamente. Conclusiones:La concentración promedio de colesterol HDL en indígenas fue significativamente menor (p<0,003) que en mestizos. Los criterios diagnósticos establecidos mostraron que las prevalencias de hipoalfalipoproteinemia en ambas poblaciones son similares a las de otras poblaciones abiertas. En mestizos, concentraciones de colesterol HDL>35mg/dl son protectoras para IM, pero será necesario establecer este punto de corte en población indígena. Cada población debe establecer sus criterios diagnósticos para hipoalfalipoproteinemia (AU)

Background and objectives: In the Mexican Mestizo and Indian populations it is unknown the diagnostic criteria (DC) and associated risk of myocardial infarction (MI) for the HDL-cholesterol (HDL-c). We aimed to establish, in a Mexican adult population without cardiovascular risk factors, their HDL-c concentrations, the DC for hypoalphalipoproteinemia and prevalence base on the percentile-10 and the risk associated with MI, as well as the threshold (TH) associated with cardiovascular protection.Subjects and methodsIn 826 adult Mestizos, 98 Indians and 155 Mestizos with MI for the first time the average HDL-c serum concentrations were determined. Then the percentile and statistical analysis were carried out.ResultsThe average HDL-c (mg/dl) concentrations for Mestizos and Indians were 43.2 and 37.2 and the ones inferior to the percentile-10 were <30 and <26, respectively. In Mestizos, HDL-c concentrations of ≤35mg/dl (odds ratio [OR] 1.91, 95% confidence interval [95%CI] 1.3-2.8, P=.001) were associated with MI and those >35 (OR 0.52, IC 95% 0.36-0.76, P=.001) were associated with a cardiovascular protection of 52%. The hypoalphalipoproteinemia prevalences in Mestizos and Indians were: for the percentile-10 DC 9 and 11% and for the TH associated with MI ≤35, 26 and 54%, respectively. Conclusions: The Indians average HDL-c concentration was significantly lower (P<.003) than for Mestizos. The established DC showed that the hypoalphalipoproteinemia prevalences in both populations were similar to those for other open populations. In Mestizos, HDL-c concentrations >35mg/dl are protective for MI, but it will be necessary to establish this TH for the Indian population. Each population should establish its own DC for hypoalphalipoproteine mia (AU)

[Diagnostic criteria for hypoalphalipoproteinemia and the threshold associated with cardiovascular protection in a Mexican Mestizo population]. / Criterio diagnóstico para hipoalfalipoproteinemia y punto de corte asociado con protección cardiovascular en una población mestiza mexicana.

BACKGROUND AND OBJECTIVES: In the Mexican Mestizo and Indian populations it is unknown the diagnostic criteria (DC) and associated risk of myocardial infarction (MI) for the HDL-cholesterol (HDL-c). We aimed to establish, in a Mexican adult population without cardiovascular risk factors, their HDL-c concentrations, the DC for hypoalphalipoproteinemia and prevalence base on the percentile-10 and the risk associated with MI, as well as the threshold (TH) associated with cardiovascular protection. SUBJECTS AND METHODS: In 826 adult Mestizos, 98 Indians and 155 Mestizos with MI for the first time the average HDL-c serum concentrations were determined. Then the percentile and statistical analysis were carried out. RESULTS: The average HDL-c (mg/dl) concentrations for Mestizos and Indians were 43.2 and 37.2 and the ones inferior to the percentile-10 were <30 and <26, respectively. In Mestizos, HDL-c concentrations of ≤ 35 mg/dl (odds ratio [OR] 1.91, 95% confidence interval [95%CI] 1.3-2.8, P=.001) were associated with MI and those >35 (OR 0.52, IC 95% 0.36-0.76, P=.001) were associated with a cardiovascular protection of 52%. The hypoalphalipoproteinemia prevalences in Mestizos and Indians were: for the percentile-10 DC 9 and 11% and for the TH associated with MI ≤ 35, 26 and 54%, respectively. CONCLUSIONS: The Indians average HDL-c concentration was significantly lower (P<.003) than for Mestizos. The established DC showed that the hypoalphalipoproteinemia prevalences in both populations were similar to those for other open populations. In Mestizos, HDL-c concentrations > 35 mg/dl are protective for MI, but it will be necessary to establish this TH for the Indian population. Each population should establish its own DC for hypoalphalipoproteinemia.